Detail akcie Ionis Pharmaceutcls online

Business Summary: Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Ionis Pharmaceuticals Inc revenues decreased 12% to $514M. Net loss increased from $23.4M to $207.2M. Revenues reflect Collaborative agreement revenue decrease of 34% to $253.8M, Other commercial revenue decrease of 6% to $18.1M. Higher net loss reflects Ionis operations segment loss increase from $7M to $219.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.1493 to -$1.25426.